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The International Conference on Harmonisation of
Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) is a project that brings together the regulatory
authorities of Europe, Japan and the United States and experts from the pharmaceutical
industry in the three regions to discuss scientific and technical aspects of pharmaceutical
product registration. The purpose of ICH is to reduce or obviate the need to duplicate the
testing carried out during the research and development of new medicines by
recommending ways to achieve greater harmonisation in the interpretation and
application of technical guidelines and requirements for product registration.
Harmonisation would lead to a more economical use of human, animal and material
resources, and the elimination of unnecessary delay in the global development and
availability of new medicines while maintaining safeguards on quality, safety, and
efficacy, and regulatory obligations to protect public health.
1. What is the purpose of ICH?
The objective of ICH is to increase international harmonisation of technical requirements
to ensure that safe, effective, and high quality medicines are developed and registered in
the most efficient and cost-effective manner. These activities have been undertaken to
promote public health, prevent unnecessary duplication of clinical trials in humans, and
minimize the use of animal testing without compromising safety and effectiveness.
2. What does ICH stand for?
The complete name of ICH is the “International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for Human Use”.
3. What is ICH?
ICH is a joint initiative involving both regulators and research-based industry
representatives of the European Union, Japan and the USA in scientific and technical
discussions of the testing procedures required to assess and ensure the safety, quality
and efficacy of medicines.
4. Which Drug Regulatory Authorities have implemented ICH Guidelines?
In addition to the Drug Regulatory Authorities (DRAs) of Europe, Japan and the US, many
other DRAs worldwide have chosen to implement some or all of the ICH Guidelines in
their regulations. For further information it is suggested to contact individual DRAs.
5. How can I get news on new ICH Guidelines?
You can register for the RSS feed on the ICH website to receive a notice everytime a new
Guideline is added or modified on the website. Also, on the home page of the ICH
website, you can refer to the news section which will inform you of any new Guideline
published.
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The ICH topics are divided into four categories and ICH topic codes
are assigned according to these categories:
Quality Guidelines
Harmonisation achievements in the Quality area include pivotal milestones such as the
conduct of stability studies, defining relevant thresholds for impurities testing and a
more flexible approach to pharmaceutical quality based on Good Manufacturing Practice
(GMP) risk management.
Exclusive example of all quality guidelines:
Stability Q1A – Q1F
Q1A(R2) Stability Testing of New Drug Substances and Products
Q1B Stability Testing: Photostability Testing of New Drug Substances and
Products
Q1C Stability Testing for New Dosage Forms
Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug
Substances and Products
Q1E Evaluation of Stability Data
Q1F Stability Data Package for Registration Applications in Climatic Zones
III and IV
Analytical Validation Q2
Q2(R1)Validation of Analytical Procedures: Text and Methodology
Impurities Q3A – Q3D
Q3A(R2) Impurities in New Drug Substances
Q3B(R2) Impurities in New Drug Products
Q3C(R5) Impurities: Guideline for Residual Solvents
Q3D Impurities: Guideline for Metal Impurities
Pharmacopoeias Q4 – Q4B
Q4 Pharmacopoeias
Q4A Pharmacopoeial Harmonisation
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Q4BE Valuation and Recommendation of Pharmacopoeial Texts for Use in
the ICH Regions
Quality of Biotechnological Products Q5A – Q5E
Q5A(R1) Viral Safety Evaluation of Biotechnology Products Derived from Cell
Lines of Human or Animal Origin
Q5B Analysis of the Expression Construct in Cells Used for Production of r-
DNA Derived Protein Products
Q5C Stability Testing of Biotechnological/Biological Products
Q5D Derivation and Characterisation of Cell Substrates Used for Pr
oduction of Biotechnological/Biological Products
Q5E Comparability of Biotechnological/Biological Products Subject to
Changes in their Manufacturing Process
Specifications Q6A- Q6B
Q6A Specifications : Test Procedures and Acceptance Criteria for New Drug
Substances and New Drug Products: Chemical Substances
Q6B Specifications : Test Procedures and Acceptance Criteria for
Biotechnological/Biological Products
Good Manufacturing Practice Q7
Q7 Good Manufacturing Practice Guide for Active Pharmaceutical
Ingredients
Pharmaceutical Development Q8
Q8(R2) Pharmaceutical Development
Quality Risk Management Q9
Q9 Quality Risk Management
Pharmaceutical Quality System Q10
Q10 Pharmaceutical Quality System
Development and Manufacture of Drug Substances Q11
Q11 Development and Manufacture of Drug Substances (Chemical Entities
and Biotechnological/Biological Entities)
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Safety Guidelines
ICH has produced a comprehensive set of safety Guidelines to uncover potential risks
like carcinogenicity, genotoxicity and reprotoxicity. A recent breakthrough has been a
non-clinical testing strategy for assessing the QT interval prolongation liability: the single
most important cause of drug withdrawals in recent years.
Efficacy Guidelines
The work carried out by ICH under the Efficacy heading is concerned with the design,
conduct, safety and reporting of clinical trials. It also covers novel types of medicines
derived from biotechnological processes and the use of pharmacogenetics/genomics
techniques to produce better targeted medicines.
Multidisciplinary Guidelines
Those are the cross-cutting topics which do not fit uniquely into one of the Quality, Safety
and Efficacy categories. It includes the ICH medical terminology (MedDRA), the Common
Technical Document (CTD) and the development of Electronic Standards for the Transfer
of Regulatory Information (ESTRI).
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